1. Introduction

Computational Biology Regulation refers to the legal, constitutional, ethical, scientific and administrative framework governing the use of computers, algorithms, artificial intelligence (AI), mathematical modelling and computational techniques to understand, analyse, predict and manipulate biological systems.

Computational biology combines several disciplines:

Biology and molecular genetics.

Computer science and artificial intelligence.

Bioinformatics and genomic sequencing.

Systems biology and biological modelling.

Computational drug discovery.

Machine learning in medical diagnosis.

Synthetic biology and genetic engineering.

Population genomics and biological databases.

It has become particularly important in drug development, precision medicine, vaccine research, genetic disease prediction, epidemiological surveillance, biotechnology manufacturing and personalised healthcare.

However, computational biological systems can create serious legal concerns involving privacy, genetic discrimination, scientific reliability, informed consent, intellectual property, algorithmic bias, cybersecurity, public health and institutional accountability.

The central legal question is:

To what extent should the law permit computational systems to analyse, predict, classify or influence biological processes without compromising human dignity, individual autonomy, privacy, public safety and scientific accountability?

2. Nature and Scope of Computational Biology Regulation

Computational biology regulation is not governed by one comprehensive statute. It operates through overlapping areas of law.

The regulation must distinguish between computational research that merely analyses biological information and computational systems that directly influence medical treatment, genetic modification or biological experimentation. The latter generally require more stringent safeguards.

3. Constitutional Framework in India

Computational biology regulation in India must comply with constitutional guarantees.

A. Article 14 – Equality and Non-Arbitrariness

Article 14 prohibits arbitrary state action and discriminatory treatment.

It becomes relevant when computational biological systems are used to:

Classify individuals according to genetic characteristics.

Predict hereditary disease risks.

Determine eligibility for healthcare.

Allocate medical resources through algorithms.

Identify individuals as genetically high-risk.

Make employment or insurance-related decisions using biological predictions.

A government authority cannot rely exclusively on an unvalidated algorithm to make consequential decisions without appropriate safeguards.

B. Article 19(1)(a) – Freedom of Expression and Scientific Research

Scientific research, publication and exchange of scientific information may receive constitutional protection under freedom of expression.

Restrictions on computational biological research must satisfy applicable constitutional requirements, including Article 19(2) where freedom of expression is restricted.

C. Article 21 – Life, Liberty, Privacy and Dignity

Article 21 is particularly important because biological and genomic information can reveal intimate characteristics of an individual.

Its protection may extend to:

Genetic privacy.

Reproductive autonomy.

Medical confidentiality.

Bodily integrity.

Informational self-determination.

Protection against involuntary biological profiling.

D. Article 47 – Public Health

Article 47 directs the State to improve public health.

It provides an important constitutional policy foundation for regulating computational biology used in disease surveillance, drug discovery, epidemiological prediction and healthcare delivery.

However, public-health objectives do not automatically justify unrestricted access to personal genomic information.

4. Statutory and Regulatory Framework in India

A. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 is relevant to computational biology because genomic, medical and biological information can constitute digital personal data when it relates to an identifiable individual.

Important regulatory requirements include:

Lawful processing of personal data.

Notice and consent, where applicable.

Compliance with statutory grounds for processing.

Appropriate security safeguards.

Restrictions and conditions concerning processing and disclosure.

Rights of individuals as Data Principals.

Accountability of Data Fiduciaries.

Breach-related obligations.

Application to computational biology: A company operating a genomic prediction platform cannot assume that collecting genetic information for one research purpose automatically permits its use for commercial drug discovery, insurance analytics or unrelated AI training.

The Digital Personal Data Protection Rules, 2025 were notified on 13 November 2025. Their commencement is phased, so the applicable provisions and enforcement dates must be examined for each processing activity.

MeitY+1

An important qualification is that the Act does not create a separate statutory category called sensitive personal data for genetic information. Nevertheless, genetic information may warrant particularly strong protection under constitutional privacy principles and applicable research ethics requirements.

B. Information Technology Act, 2000

The Information Technology Act, 2000 is relevant to:

Unauthorised access to biological databases.

Data theft and cyberattacks.

Compromise of genomic repositories.

Computer-related offences.

Unlawful disclosure of confidential information.

Section 43 and Section 66 address specified unauthorised computer-related activities and offences. Section 72 addresses breach of confidentiality and privacy in the circumstances specified by that provision.

C. Patents Act, 1970

The Patents Act is important for computational biological inventions.

Relevant provisions include:

Example: A mathematical algorithm that predicts protein folding is not automatically patentable merely because it has commercial value. However, a properly claimed technical implementation may be examined for patentability if it satisfies the statutory requirements and avoids the exclusions.

D. Drugs and Cosmetics Act, 1940 and Medical Devices Rules, 2017

These laws become relevant when computational biology is converted into a medical product or clinical decision-making system.

Examples include:

AI-based diagnostic software.

Computational pathology systems.

Genomic diagnostic platforms.

Software-assisted treatment recommendations.

Computationally designed medical devices.

Biological testing and diagnostic equipment.

The Medical Devices Rules, 2017 adopt a risk-based classification system consisting of Classes A, B, C and D.

The CDSCO expressly recognises software as a possible medical device when it is intended for specified medical purposes. Its guidance document on Medical Device Software, dated 21 July 2026, provides further regulatory guidance.

CDSCO+2

E. Biological Research and Biosafety Regulation

Computational biology may involve the analysis or design of genetically modified organisms and other biological materials.

The following framework is relevant:

Environment (Protection) Act, 1986.

Rules, 1989 concerning hazardous microorganisms and genetically engineered organisms or cells.

Gene Technology-related regulatory requirements.

Department of Biotechnology biosafety guidelines.

Institutional Biosafety Committee requirements.

Institutional Ethics Committee requirements.

ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017.

The ICMR guidelines specifically address biological materials, biobanks, datasets, data mining, cloud computing, access control, encryption and privacy. They recognise that research using existing datasets can still require ethical scrutiny.

Indian Council of Medical Research+1

5. Important Areas of Computational Biology Regulation

A. Regulation of Genomic Data and Bioinformatics

Genomic databases contain information about DNA sequences, inherited conditions, mutations, ancestry and biological relationships.

Legal issues include:

Consent for collection and sequencing.

Secondary use of genomic information.

Data sharing with foreign research institutions.

Commercialisation of genomic databases.

Re-identification of supposedly anonymous data.

Disclosure of hereditary disease information.

Rights of family members affected by genomic discoveries.

Illustration: A research institution collects DNA samples from 10,000 participants to study hereditary cancer. A biotechnology company later uses the resulting genomic database to develop a commercial prediction system.

The legal questions include whether the original consent covered commercial use, whether ethical approval permits the secondary use, whether personal data requirements are satisfied and whether appropriate benefit-sharing arrangements exist.

B. Regulation of AI-Based Biological Modelling

AI systems can predict:

Protein structures.

Genetic mutations.

Drug interactions.

Disease susceptibility.

Cellular responses.

Gene-expression patterns.

Biological pathways.

Regulatory concerns arise when inaccurate predictions are used in consequential decisions.

For example, an AI system may incorrectly predict that an individual has a high probability of developing a hereditary disease. If a hospital relies on that prediction without confirmatory testing, the patient may suffer unnecessary treatment, psychological harm or financial consequences.

The appropriate legal safeguards include:

Independent scientific validation.

Documentation of training datasets.

Bias and error assessment.

Human oversight.

Explainability appropriate to the intended use.

Periodic performance monitoring.

Clear allocation of liability.

C. Computational Drug Discovery

Computational systems are increasingly used to identify drug candidates and predict molecular interactions.

The regulatory framework must distinguish between:

Computer-generated drug candidates.

Laboratory validation.

Preclinical testing.

Clinical trials.

Manufacturing.

Marketing authorisation.

An AI-generated prediction does not establish that a drug is safe or effective.

The developer, manufacturer, clinical investigator and sponsor may have different legal responsibilities depending on their activities.

D. Regulation of Computational Clinical Trials

Computational biology can support patient selection, statistical analysis, trial simulations and biomarker identification.

The main legal concerns are:

Informed consent.

Research ethics approval.

Scientific validity.

Patient confidentiality.

Statistical reliability.

Trial registration and reporting.

Adverse-event monitoring.

Responsibility for algorithmic errors.

A computationally designed clinical trial cannot avoid ordinary clinical-trial safeguards merely because its initial design was generated by an algorithm.

E. Synthetic Biology and Computational Design

Computational models may be used to design genetic circuits, biological pathways and synthetic organisms.

This creates a distinction between legitimate research and potentially dangerous biological applications.

Regulation should consider:

Biological containment.

Environmental release.

Genetic stability.

Unintended mutations.

Pathogenicity.

Dual-use research.

Laboratory security.

Long-term environmental monitoring.

A computer simulation alone may not require the same regulatory approval as an actual genetic modification experiment. However, once the model is translated into biological experimentation, the applicable biosafety framework becomes important.

6. Important Indian Judicial Decisions

There is currently no single comprehensive Supreme Court judgment establishing a complete regulatory doctrine for computational biology. The following decisions provide important legal principles that apply by analogy or directly to particular computational biology activities.

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

Leading constitutional authority

Court: Supreme Court of India.

Subject: Right to privacy.

Legal principle:

The nine-judge Bench unanimously recognised privacy as a fundamental right protected under the Constitution.

The judgment established that privacy includes:

Informational privacy.

Individual autonomy.

Personal dignity.

Control over personal information.

Protection against unjustified interference.

Application to computational biology:

Genomic databases and computational biological platforms can reveal extremely intimate information about individuals.

Therefore, governmental or private processing of genomic data must be assessed against the constitutional protection of privacy.

The judgment provides the foundation for challenging disproportionate genetic surveillance, involuntary genomic profiling and unjustified disclosure of biological information.

Indian Kanoon+1

2. Selvi v. State of Karnataka (2010) 7 SCC 263

Court: Supreme Court of India.

Subject: Involuntary narco-analysis, polygraph examination and brain electrical activation profile tests.

Legal principle:

The Supreme Court held that involuntary administration of the impugned techniques violated constitutional protections, particularly Articles 20(3) and 21.

The judgment discussed DNA profiling separately from the techniques under consideration.

Application to computational biology:

It is relevant where authorities seek to compel biological or neurological information from individuals.

For example:

Involuntary neural-data collection.

Compulsory biological profiling.

Computational analysis of brain activity.

Criminal investigations using biological information.

The judgment supports the importance of bodily integrity and protection against compelled testimonial extraction. It should not be interpreted as establishing a blanket prohibition on every legally authorised DNA examination.

Supreme Court+1

3. Sharda v. Dharmpal (2003) 4 SCC 493

Court: Supreme Court of India.

Subject: Medical examination in matrimonial proceedings.

Legal principle:

The Court recognised that medical examination may be ordered in appropriate circumstances, but the power must be exercised judicially and with due regard to competing rights.

Application:

The case is relevant to disputes involving court-directed medical or genetic examinations.

It supports the proposition that bodily privacy is not absolute, but interference requires a legally justifiable basis and judicial scrutiny.

4. District Registrar and Collector v. Canara Bank (2005) 1 SCC 496

Court: Supreme Court of India.

Subject: Privacy and access to private records.

Legal principle:

The judgment considered the protection of private documents and the limits of state access to personal information.

Application:

It provides relevant reasoning for the protection of confidential genomic records, research databases and personal biological information against unjustified access.

5. Abhishek Paruthi v. State (NCT of Delhi) (2023)

Court: Delhi High Court.

Subject: DNA examination and privacy.

Legal principle:

The decision discussed the application of proportionality to DNA testing, including the importance of assessing legitimate objectives and the privacy consequences of compelled testing.

Application:

The case is relevant to computational biological systems that use DNA profiles to establish identity, family relationships or other personal characteristics.

Indian Kanoon

7. Important Indian Patent and Biotechnology Decisions

These decisions are especially important because computational biology frequently produces software-based diagnostic inventions, genetic testing technologies and computer-assisted biological processes.

6. Ferid Allani v. Union of India (2019) SCC OnLine Del 11867

Court: Delhi High Court.

Subject: Patentability of computer-related inventions under Section 3(k).

Legal principle:

The Court recognised that computer-related inventions should not automatically be rejected merely because they involve computer programmes.

The existence of a technical effect or technical contribution is important when determining patentability.

Application to computational biology:

A computational biology invention involving:

Protein-folding algorithms.

Genomic sequence analysis.

Biological simulation software.

Computational drug-design platforms.

Molecular interaction prediction.

may be examined for patentability if the claimed invention demonstrates the required technical contribution and satisfies the remaining statutory requirements.

However, Ferid Allani does not make algorithms independently patentable.

7. Blackberry Limited v. Assistant Controller of Patents and Designs (2024)

Court: Delhi High Court.

Subject: Algorithm-related patentability under Section 3(k).

Legal principle:

The Court distinguished between a mere set of instructions determining the flow of data and an implementation producing a genuine technical effect or contribution.

The mere presence of an algorithm is insufficient for patent protection.

Application:

A biological algorithm that merely calculates a probability of disease may face Section 3(k) objections.

A computer-implemented technical system that produces a qualifying technical contribution must be examined on its actual implementation and patent claims.

IP India+1

8. Ab Initio Technology LLC v. Assistant Controller of Patents and Designs (2024)

Court: Delhi High Court.

Subject: Technical effect in computer-related inventions.

Legal principle:

The Court explained that technical effect is not confined to changes in physical hardware. Improvements in computational processing can also be relevant.

Application:

A computational biology system that materially improves the speed or efficiency of genomic processing, molecular simulation or biological computation may rely on this reasoning when establishing technical contribution.

9. Sequenom Inc. v. The Controller of Patents (2025), 2025:DHC:8926

Court: Delhi High Court.

Decision: 9 October 2025.

Subject: Patentability of prenatal genetic screening and diagnostic methods under Section 3(i).

Importance:

The case concerned inventions involving methylation-based enrichment of fetal nucleic acid from maternal biological samples for prenatal testing.

The Court examined the distinction between screening, diagnosis, diagnostic tools and diagnostic processes.

Its important propositions include:

A diagnostic process may be excluded under Section 3(i).

Diagnostic tools and products are not automatically excluded.

Software-based diagnostic tools must also satisfy Section 3(k).

The distinction between in-vitro and in-vivo processes does not automatically avoid Section 3(i).

The actual technical nature and function of the claimed invention matter.

Application to computational biology:

This is one of the most directly relevant Indian decisions for computational genomics and bioinformatics.

For example, an AI-powered prenatal genomic platform must be assessed according to whether the claimed invention is a diagnostic process, a diagnostic product, a software tool or a technically qualifying implementation.

The judgment also demonstrates that describing a diagnostic invention as a screening technology does not automatically take it outside Section 3(i).

Indian Kanoon+2

10. EMD Millipore Corporation v. Assistant Controller of Patents and Designs (2025), 2025:DHC:8928

Court: Delhi High Court.

Decision: 9 October 2025.

Subject: Infrared-based quantification of biomolecules and Section 3(i).

Legal importance:

The Court considered whether an in-vitro method of quantifying biomolecules constituted an excluded diagnostic process.

The decision distinguished methods of diagnosis from technical methods of biomolecule measurement that do not themselves perform a clinical diagnostic function.

Application:

Computational biology inventions involving biomolecule quantification, molecular measurement and analytical platforms may benefit from this distinction.

However, patentability remains dependent on the actual claims and the other requirements of the Patents Act.

Ali on Patents+1

11. Novartis AG v. Union of India (2013) 6 SCC 1

Court: Supreme Court of India.

Subject: Pharmaceutical patentability and Section 3(d).

Legal principle:

The Court interpreted Section 3(d) in the context of preventing evergreening and maintaining a balance between pharmaceutical innovation and public health.

Application:

Computationally developed medicines, molecular compounds and biological products must satisfy the applicable patentability standards.

An AI-generated drug candidate does not receive patent protection merely because it was developed through sophisticated computational techniques.

12. Chinese University of Hong Kong v. Assistant Controller of Patents and Designs (2023) SCC OnLine Mad 6372

Court: Madras High Court.

Subject: Diagnostic methods and Section 3(i).

Legal principle:

The decision examined the scope of diagnostic-method exclusions, including the distinction between screening and diagnostic techniques.

Application:

It is relevant to genomic screening systems, computational prenatal testing and molecular diagnostic inventions.

It must be read together with the later Delhi High Court decisions, particularly Sequenom (2025).

8. International Legal Framework

Computational biology operates internationally because biological datasets, research institutions, cloud infrastructure and biotechnology companies frequently cross national boundaries.

A. European Union

The following instruments are particularly relevant:

General Data Protection Regulation (GDPR).

EU Medical Device Regulation 2017/745.

EU In Vitro Diagnostic Medical Devices Regulation 2017/746.

EU Artificial Intelligence Act.

Convention on Human Rights and Biomedicine (Oviedo Convention), where applicable.

The GDPR gives particular importance to genetic data and health data under Article 9.

The EU framework is relevant to computational genomic platforms processing genetic information of European individuals.

B. United States

Important legislation and regulatory frameworks include:

Health Insurance Portability and Accountability Act (HIPAA).

Genetic Information Nondiscrimination Act (GINA).

Clinical Laboratory Improvement Amendments (CLIA).

Federal Food, Drug, and Cosmetic Act.

FDA regulation of software as a medical device.

Common Rule for federally supported human-subject research.

HIPAA regulates protected health information held by covered entities and business associates. It does not automatically cover every consumer genomic database.

GINA provides specific protections against certain forms of genetic discrimination in health insurance and employment, but does not cover every form of insurance.

C. International Biological and Genetic Research Standards

Relevant international instruments include:

Convention on Biological Diversity, 1992.

Nagoya Protocol, 2010.

Cartagena Protocol on Biosafety, 2000.

UNESCO Universal Declaration on the Human Genome and Human Rights, 1997.

International Health Regulations, 2005.

These instruments address biological-resource access, benefit-sharing, biosafety, human genomic dignity and public-health cooperation.

They provide important principles for multinational computational biology projects.

9. Civil, Criminal and Institutional Liability

Computational biology can generate liability at several levels.

A. Negligence

Suppose a computational platform incorrectly identifies a genetic mutation and a physician relies on the result to prescribe an inappropriate treatment.

Potential liability may arise from:

Defective software.

Inadequate validation.

Failure to disclose known limitations.

Negligent interpretation.

Failure to undertake confirmatory testing.

Unreasonable clinical reliance.

The legal assessment will depend on the applicable standard of care, causation, foreseeability and the responsibility of each participant.

B. Product Liability

Where computational biological software qualifies as a product or service under applicable legislation, defective design, inadequate warnings or deficient performance may give rise to consumer or other statutory liability.

The Consumer Protection Act, 2019 may be relevant to defective products and deficient services.

C. Institutional Liability

Universities, hospitals, research laboratories and biotechnology companies may face legal consequences for:

Unauthorised data sharing.

Inadequate cybersecurity.

Research conducted without appropriate approval.

Scientific manipulation.

Misrepresentation of predictive accuracy.

Failure to supervise outsourced computational services.

D. Criminal Liability

Depending on the conduct, relevant criminal and regulatory provisions may apply to:

Unauthorised access to biological databases.

Identity theft.

Fraudulent genetic testing.

Falsification of research records.

Illegal biological experimentation.

Prohibited genetic selection or sex determination.

Unlawful handling of regulated biological materials.

Criminal liability must be based on the ingredients of a specific offence; an inaccurate algorithmic prediction alone does not automatically constitute a crime.

10. Computational Biology and Intellectual Property Rights

Intellectual property is one of the most complicated aspects of computational biology because biological discoveries and computational inventions frequently overlap.

A. Ownership of Computationally Generated Biological Discoveries

Questions arise concerning ownership of:

AI-generated molecular structures.

Computationally predicted proteins.

Genomic databases.

Biological simulation models.

Machine-generated drug candidates.

Synthetic biological sequences.

The law must distinguish between ownership of software, ownership of data, patent rights over qualifying inventions and rights relating to biological materials.

B. AI and Inventorship

Under the Indian Patents Act, inventorship is linked to the legal requirements for identifying the inventor. AI systems are not automatically recognised as legal inventors.

A human researcher or research team may potentially claim inventorship where their contribution satisfies the applicable legal test.

C. Database Protection

Genomic and biological databases may receive protection through:

Copyright in qualifying original compilations.

Contractual confidentiality.

Trade-secret protection.

Copyright in software.

Patent protection for qualifying technical inventions.

However, copyright does not automatically confer exclusive ownership over biological facts or naturally occurring DNA sequences.

11. Important International Judicial Decisions

The following foreign judgments provide useful comparative principles. They are persuasive rather than binding in Indian courts.

These cases help explain the international tension between biological discoveries, computer-implemented inventions, diagnostic methods and AI-generated innovations.

12. Major Regulatory Challenges

Computational biology creates several emerging regulatory difficulties.

1. Algorithmic opacity

A biological algorithm may produce a prediction without providing a scientifically understandable explanation.

Regulators must determine whether the model is sufficiently transparent for its intended purpose.

2. Genetic discrimination

Genetic predictions may be misused by employers, insurers, educational institutions or government authorities.

3. Data re-identification

Removing names from genomic datasets does not necessarily make them anonymous. Genetic information may be linked with other databases to identify individuals.

4. Scientific reproducibility

A model may produce different results when trained using different datasets or computational assumptions.

5. Cross-border data transfers

International research collaborations create questions concerning data-protection compliance, research consent, institutional responsibility and access to biological information.

6. Dual-use biological research

Computational tools can support beneficial research but may also facilitate harmful biological applications.

7. Regulatory fragmentation

Different authorities may regulate data, medical devices, biological materials, research ethics and intellectual property without a single integrated oversight mechanism.

13. Proposed Computational Biology Accountability Governance Doctrine

A useful emerging regulatory framework can be developed around the following principles. This is a proposed analytical doctrine, not an existing statutory doctrine established by an Indian court.

Seven pillars of computational biology governance

Scientific validity

Computational biological findings must be supported by reliable methods, reproducible evidence and independent validation.

Genetic privacy

Biological and genomic information must be processed according to applicable privacy laws and research safeguards.

Human autonomy

Individuals must receive appropriate information and protection against unjustified biological testing or profiling.

Algorithmic accountability

Developers and institutions must maintain documentation, audit trails and appropriate explanations of consequential predictions.

Biosafety

Computationally designed biological experiments must be assessed for environmental and public-health risks before implementation.

Institutional responsibility

Research institutions, manufacturers, hospitals and regulatory authorities must have clearly defined responsibilities.

Remedies and compensation

Individuals affected by unlawful data processing, defective systems or negligent research must have access to appropriate legal remedies.

14. Recommended Regulatory Compliance Framework

An institution conducting computational biology research in India should adopt the following compliance process.

The following distinction is especially important:

Pure computational research does not automatically require medical-device authorisation.

Software intended for a medical purpose may qualify as a regulated medical device.

Computational predictions involving human biological data may trigger privacy and ethical obligations.

Actual genetic engineering or biological experimentation may trigger separate biosafety requirements.

15. Important Legal Questions for Future Litigation

Computational biology regulation is likely to generate disputes involving the following questions:

Can a person challenge a government decision based exclusively on a genomic algorithm?

Can an individual withdraw consent after their genomic data has been incorporated into a research database?

Who owns a biological discovery predicted by an AI system?

Can a biotechnology company commercially exploit genomic information originally collected for public research?

Who is responsible when an AI-generated molecular prediction causes medical injury?

Can genetic information be used in insurance underwriting?

Can an institution disclose hereditary disease information to relatives without the participant's consent?

Should computationally designed biological experiments require additional regulatory approval?

Can a biological algorithm qualify for patent protection under Section 3(k)?

What standards should courts apply when evaluating scientific evidence generated through computational biological systems?

These questions demonstrate the need for a specialised framework connecting constitutional law, biotechnology regulation, data protection, intellectual property and administrative accountability.

16. Conclusion

Computational Biology Regulation is an emerging interdisciplinary field that governs the intersection of biological science, computational technologies, artificial intelligence and legal responsibility.

In India, its legal framework is distributed across the Constitution, Digital Personal Data Protection Act, 2023, Information Technology Act, 2000, Patents Act, 1970, Drugs and Cosmetics Act, 1940, Medical Devices Rules, 2017, environmental and biosafety legislation, and biomedical research ethics guidelines.

The most important judicial foundations include:

Justice K.S. Puttaswamy v. Union of India — informational privacy and constitutional dignity.

Selvi v. State of Karnataka — bodily integrity and protection against involuntary scientific techniques.

Sharda v. Dharmpal — judicially justified medical examination.

Ferid Allani v. Union of India — technical contribution in computer-related inventions.

Blackberry Ltd. v. Assistant Controller of Patents — algorithmic patentability.

Sequenom Inc. v. Controller of Patents — diagnostic biotechnology and patent exclusions.

EMD Millipore Corporation v. Assistant Controller of Patents — biomolecule quantification and diagnostic patentability.

The central principle is that computational innovation must remain scientifically reliable, constitutionally proportionate, ethically responsible and legally accountable. Computational biology should facilitate medical and scientific progress without turning human biological information into an unrestricted commercial, governmental or technological resource.

Research note: The 2025 Delhi High Court patent judgments are particularly important recent authorities. Their interpretations should be read alongside the statutory text and subsequent developments; they are not a substitute for a comprehensive computational biology statute.

For further legal research, the primary materials include:

ICMR National Ethical Guidelines, 2017

Digital Personal Data Protection Rules, 2025

CDSCO Medical Device Regulatory Framework

Sequenom Inc. v. Controller of Patents (2025)

EMD Millipore (2025)